Filing Flows › Chemours (CC) › Q3 2026 › vs Q3 2025
Chemours (CC) Q3 2026 vs Q3 2025 (year over year)
Chemours's revenue rose $45.0M (+3%) from $1.5B in Q3 2025 to $1.5B in Q3 2026. The biggest changes: All Segments +$44.0M (+3%); Other Non-Reportable Segment +$1.0M (+8%). Gross margin 15.0% against 15.6% (-0.6 pts).
Chemours, Q3 2026: revenue $1.5B (+3% year over year), operating margin 14.4%, net earnings $196M, operating cash flow $149M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 15.0% | 15.6% | -0.6 pts |
| Operating margin | 14.4% | 2.5% | +11.9 pts |
| Net margin | 12.7% | 3.1% | +9.7 pts |
| Free cash flow margin | 6.4% | 7.0% | -0.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| All Segments | $1.5B | $1.5B | $44.0M | +3% |
| Other Non-Reportable Segment | $13.0M | $12.0M | $1.0M | +8% |
| Revenue | $1.5B | $1.5B | $45.0M | +3% |
| Gross profit | $231M | $233M | −$2.0M | -0.9% |
| Cost of revenue | $1.3B | $1.3B | $47.0M | +4% |
| Operating profit | $222M | $38.0M | $184M | +484% |
| Operating expenses | $9.0M | $195M | −$186M | -95% |
| Pre-tax earnings | $222M | $38.0M | $184M | +484% |
| Net earnings | $196M | $46.0M | $150M | +326% |
| Income tax | $26.0M | −$8.0M | $34.0M | — |
| Depreciation | $79.0M | $81.0M | −$2.0M | -2% |
| Share-based compensation | $4.0M | $5.0M | −$1.0M | -20% |
| Working capital & other | $130M | −$14.0M | $144M | — |
| Operating cash flow | $149M | $146M | $3.0M | +2% |
| Free cash flow (OCF − capex) | $98.0M | $105M | −$7.0M | -7% |
| Capital expenditures | $51.0M | $41.0M | $10.0M | +24% |
Questions
How much did Chemours's revenue grow year over year in Q3 2026?
Chemours's revenue rose $45.0M (+3%) from $1.5B in Q3 2025 to $1.5B in Q3 2026.
What drove Chemours's revenue change in Q3 2026?
All Segments +$44.0M (+3%); Other Non-Reportable Segment +$1.0M (+8%).